GlassScriptPhysician profile
Dakshesh Patel
NPI 1720202278
$4,932.91
in general payments reported to CMS, 2019-2025
52 companies · $970 in 2025
The $970 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $230 · 2021: $26.42 · 2022: $344 · 2023: $1,100 · 2024: $1,445 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,356 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,356.14 |
| Education | $158.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $507.61 | 2019-2025 | Amyvid, Kisunla, Reyvow |
| Ucb, INC. | $450.66 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Abbvie INC. | $446.77 | 2021-2025 | |
| Pfizer INC. | $326.54 | 2023-2025 | |
| Mdd US Operations, LLC | $267.12 | 2019-2025 | Apokyn, Apokyn, Xadago |
| Acadia Pharmaceuticals INC | $228.73 | 2019-2024 | Nuplazid |
| Eisai INC. | $210.32 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $193.21 | 2023-2025 | Rexulti, Nuedexta |
| Alexion Pharmaceuticals, INC. | $172.50 | 2019-2025 | Ultomiris, Soliris |
| Astrazeneca Pharmaceuticals LP | $153.08 | 2024 | Wainua |
| Novartis Pharmaceuticals Corporation | $151.88 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $125.29 | 2022-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Argenx US, INC. | $106.94 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurocrine Biosciences, INC. | $99.70 | 2024-2025 | Ingrezza |
| Amgen INC. | $97.32 | 2019-2023 | Aimovig |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dakshesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.